A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment.

Mark MonaneKim G JohnsonB Joy SniderRaymond S TurnerJonathan D DrakeDemetrius M MaraganoreJames L BickselDaniel H JacobsJulia L OrtegaJoni HendersonYan JiangShuguang HuangJustine CoppingerIlana FogelmanTim WestJoel B Braunstein

Published in: Annals of clinical and translational neurology (2023)

These findings demonstrate the clinical utility of the PrecivityAD blood test in clinical care and may have added relevance as new AD therapies are introduced.

Keyphrases

clinical evaluation
cognitive impairment
healthcare
palliative care
white matter
resting state
quality improvement
pain management
multiple sclerosis
functional connectivity
health insurance